ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The role of the SH2 domain in c-Abl is of special interest, because it is involved both in auto-inhibition and activation of the CD [18], [20], [21], and mutations in the SH2 domain have been related to imatinib-resistance in CML patients [18], [19], [22].